Qizhi Tang, PhD, is an affiliate investigator at Gladstone Institutes. She is also a professor of surgery in the School of Medicine at UC San Francisco (UCSF), as well as a core faculty member at the UCSF Diabetes Center and the UCSF Institute of Regenerative Medicine.
Tang started medical school at Peking Union Medical College in China, and moved to the US where she obtained a PhD in immunology from the University of Illinois Chicago. After completing postdoctoral studies in immunology, she joined UCSF as an assistant adjunct professor in pathology in 2002. She joined the UCSF-Gladstone Institute of Genomic Immunology in 2022.
Tang has been studying immune cells known as T regulatory cells (Tregs) for over 20 years. Her expertise focuses in two areas. One is promoting immune tolerance to alleviate autoimmune diseases and the rejection of organ transplants. The other is improving therapies that aim to replace pancreatic cells for the treatment of type 1 diabetes. Recently, her lab has been investigating the potential of Tregs as vehicles for drug delivery.
She has been the director of the Federation of Clinical Immunology Societies’ (FOCiS) Center of Excellence at UCSF since 2014, and co-director of the JDRF Center of Excellence in Northern California since 2022. She was also director of the UCSF Transplantation Research Laboratory from 2007 to 2021.
Publications
- Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival. Wagner JC, Ronin E, Ho P, Peng Y, Tang Q. Am J Transplant. 2022 Apr 17.
- IL-6 and TNFα Drive Extensive Proliferation of Human Tregs Without Compromising Their Lineage Stability or Function. Skartsis N, Peng Y, Ferreira LMR, Nguyen V, Ronin E, Muller YD, Vincenti F, Tang Q. Front Immunol. 2021; 12:783282.
- Lung transplant recipients with idiopathic pulmonary fibrosis have impaired alloreactive immune responses. Wang P, Leung J, Lam A, Lee S, Calabrese DR, Hays SR, Golden JA, Kukreja J, Singer JP, Wolters PJ, Tang Q, Greenland JR. J Heart Lung Transplant. 2022 05; 41(5):641-653.
- Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience. Balcerek J, Shy BR, Putnam AL, Masiello LM, Lares A, Dekovic F, Acevedo L, Lee MR, Nguyen V, Liu W, Paruthiyil S, Xu J, Leinbach AS, Bluestone JA, Tang Q, Esensten JH. Front Immunol. 2021; 12:744763.
- The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes. Dong S, Hiam-Galvez KJ, Mowery CT, Herold KC, Gitelman SE, Esensten JH, Liu W, Lares AP, Leinbach AS, Lee M, Nguyen V, Tamaki SJ, Tamaki W, Tamaki CM, Mehdizadeh M, Putnam AL, Spitzer MH, Ye CJ, Tang Q, Bluestone JA. JCI Insight. 2021 09 22; 6(18).
- Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance. Muller YD, Ferreira LMR, Ronin E, Ho P, Nguyen V, Faleo G, Zhou Y, Lee K, Leung KK, Skartsis N, Kaul AM, Mulder A, Claas FHJ, Wells JA, Bluestone JA, Tang Q. Front Immunol. 2021; 12:686439.
- The Role of Regulatory T Cells in Pulmonary Arterial Hypertension. Tian W, Jiang SY, Jiang X, Tamosiuniene R, Kim D, Guan T, Arsalane S, Pasupneti S, Voelkel NF, Tang Q, Nicolls MR. Front Immunol. 2021; 12:684657.
- Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection. Parent AV, Faleo G, Chavez J, Saxton M, Berrios DI, Kerper NR, Tang Q, Hebrok M. Cell Rep. 2021 08 17; 36(7):109538.
- A Comparison of Ex Vivo Expanded Human Regulatory T Cells Using Allogeneic Stimulated B Cells or Monocyte-Derived Dendritic Cells. Lee LM, Zhang H, Lee K, Liang H, Merleev A, Vincenti F, Maverakis E, Thomson AW, Tang Q. Front Immunol. 2021; 12:679675.
- A human mutation in STAT3 promotes type 1 diabetes through a defect in CD8+ T cell tolerance. Warshauer JT, Belk JA, Chan AY, Wang J, Gupta AR, Shi Q, Skartsis N, Peng Y, Phipps JD, Acenas D, Smith JA, Tamaki SJ, Tang Q, Gardner JM, Satpathy AT, Anderson MS. J Exp Med. 2021 08 02; 218(8).
- The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. Muller YD, Nguyen DP, Ferreira LMR, Ho P, Raffin C, Valencia RVB, Congrave-Wilson Z, Roth TL, Eyquem J, Van Gool F, Marson A, Perez L, Wells JA, Bluestone JA, Tang Q. Front Immunol. 2021; 12:639818.
- Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial. Chandran S, Leung J, Hu C, Laszik ZG, Tang Q, Vincenti FG. Am J Transplant. 2021 07; 21(7):2543-2554.
- Solving the Puzzle of Immune Tolerance for β-Cell Replacement Therapy for Type 1 Diabetes. Bluestone JA, Tang Q. Cell Stem Cell. 2020 10 01; 27(4):505-507.
- Functional CRISPR dissection of gene networks controlling human regulatory T cell identity. Schumann K, Raju SS, Lauber M, Kolb S, Shifrut E, Cortez JT, Skartsis N, Nguyen VQ, Woo JM, Roth TL, Yu R, Nguyen MLT, Simeonov DR, Nguyen DN, Targ S, Gate RE, Tang Q, Bluestone JA, Spitzer MH, Ye CJ, Marson A. Nat Immunol. 2020 11; 21(11):1456-1466.
- CAR-Tregs as a Strategy for Inducing Graft Tolerance. Wagner JC, Tang Q. Curr Transplant Rep. 2020 Sep; 7(3):205-214.
- Novel In Situ Hybridization and Multiplex Immunofluorescence Technology Combined With Whole-slide Digital Image Analysis in Kidney Transplantation. Junger H, Dobi D, Chen A, Lee L, Vasquez JJ, Tang Q, Laszik ZG. J Histochem Cytochem. 2020 07; 68(7):445-459.
- Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Sawitzki B, Harden PN, Reinke P, Moreau A, Hutchinson JA, Game DS, Tang Q, Guinan EC, Battaglia M, Burlingham WJ, Roberts ISD, Streitz M, Josien R, Böger CA, Scottà C, Markmann JF, Hester JL, Juerchott K, Braudeau C, James B, Contreras-Ruiz L, van der Net JB, Bergler T, Caldara R, Petchey W, Edinger M, Dupas N, Kapinsky M, Mutzbauer I, Otto NM, Öllinger R, Hernandez-Fuentes MP, Issa F, Ahrens N, Meyenberg C, Karitzky S, Kunzendorf U, Knechtle SJ, Grinyó J, Morris PJ, Brent L, Bushell A, Turka LA, Bluestone JA, Lechler RI, Schlitt HJ, Cuturi MC, Schlickeiser S, Friend PJ, Miloud T, Scheffold A, Secchi A, Crisalli K, Kang SM, Hilton R, Banas B, Blancho G, Volk HD, Lombardi G, Wood KJ, Geissler EK. Lancet. 2020 05 23; 395(10237):1627-1639.
- Next-generation regulatory T cell therapy. Ferreira LMR, Muller YD, Bluestone JA, Tang Q. Nat Rev Drug Discov. 2019 10; 18(10):749-769.
- Supporting Survival of Transplanted Stem-Cell-Derived Insulin-Producing Cells in an Encapsulation Device Augmented with Controlled Release of Amino Acids. Chendke GS, Faleo G, Juang C, Parent AV, Bernards DA, Hebrok M, Tang Q, Desai TA. Adv Biosyst. 2019 Sep; 3(9).
- NextGen cell-based immunotherapies in cancer and other immune disorders. Azimi CS, Tang Q, Roybal KT, Bluestone JA. Curr Opin Immunol. 2019 08; 59:79-87.
- NKG2C Natural Killer Cells in Bronchoalveolar Lavage Are Associated With Cytomegalovirus Viremia and Poor Outcomes in Lung Allograft Recipients. Calabrese DR, Chong T, Wang A, Singer JP, Gottschall M, Hays SR, Golden JA, Kukreja J, Lanier LL, Tang Q, Greenland JR. Transplantation. 2019 03; 103(3):493-501.
- Adoptive Treg Cell Therapy in a Patient With Systemic Lupus Erythematosus. Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandova PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD, Autoimmunity Centers of Excellence. Arthritis Rheumatol. 2019 03; 71(3):431-440.
- Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. Savage TM, Shonts BA, Obradovic A, Dewolf S, Lau S, Zuber J, Simpson MT, Berglund E, Fu J, Yang S, Ho SH, Tang Q, Turka LA, Shen Y, Sykes M. JCI Insight. 2018 11 15; 3(22).
- Islet encapsulation therapy - racing towards the finish line? Desai TA, Tang Q. Nat Rev Endocrinol. 2018 11; 14(11):630-632.
- Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier. Esensten JH, Muller YD, Bluestone JA, Tang Q. J Allergy Clin Immunol. 2018 12; 142(6):1710-1718.
- Treg cells-the next frontier of cell therapy. Bluestone JA, Tang Q. Science. 2018 10 12; 362(6411):154-155.
- Report of the Key Opinion Leaders Meeting on Stem Cell-derived Beta Cells. Odorico J, Markmann J, Melton D, Greenstein J, Hwa A, Nostro C, Rezania A, Oberholzer J, Pipeleers D, Yang L, Cowan C, Huangfu D, Egli D, Ben-David U, Vallier L, Grey ST, Tang Q, Roep B, Ricordi C, Naji A, Orlando G, Anderson DG, Poznansky M, Ludwig B, Tomei A, Greiner DL, Graham M, Carpenter M, Migliaccio G, D'Amour K, Hering B, Piemonti L, Berney T, Rickels M, Kay T, Adams A. Transplantation. 2018 08; 102(8):1223-1229.
- Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges. Sneddon JB, Tang Q, Stock P, Bluestone JA, Roy S, Desai T, Hebrok M. Cell Stem Cell. 2018 Jun 01; 22(6):810-823.
- Suppressed calcineurin-dependent gene expression identifies lung allograft recipients at increased risk of infection. Greenland JR, Chong T, Wang AS, Martinez E, Shrestha P, Kukreja J, Hays SR, Golden JA, Singer JP, Tang Q. Am J Transplant. 2018 08; 18(8):2043-2049.
- Revealing the specificity of regulatory T cells in murine autoimmune diabetes. Spence A, Purtha W, Tam J, Dong S, Kim Y, Ju CH, Sterling T, Nakayama M, Robinson WH, Bluestone JA, Anderson MS, Tang Q. Proc Natl Acad Sci U S A. 2018 05 15; 115(20):5265-5270.
- Alloreactive fetal T cells promote uterine contractility in preterm labor via IFN-γ and TNF-α. Frascoli M, Coniglio L, Witt R, Jeanty C, Fleck-Derderian S, Myers DE, Lee TH, Keating S, Busch MP, Norris PJ, Tang Q, Cruz G, Barcellos LF, Gomez-Lopez N, Romero R, MacKenzie TC. Sci Transl Med. 2018 04 25; 10(438).
- Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. Fuchs A, Gliwinski M, Grageda N, Spiering R, Abbas AK, Appel S, Bacchetta R, Battaglia M, Berglund D, Blazar B, Bluestone JA, Bornhäuser M, Ten Brinke A, Brusko TM, Cools N, Cuturi MC, Geissler E, Giannoukakis N, Golab K, Hafler DA, van Ham SM, Hester J, Hippen K, Di Ianni M, Ilic N, Isaacs J, Issa F, Iwaszkiewicz-Grzes D, Jaeckel E, Joosten I, Klatzmann D, Koenen H, van Kooten C, Korsgren O, Kretschmer K, Levings M, Marek-Trzonkowska NM, Martinez-Llordella M, Miljkovic D, Mills KHG, Miranda JP, Piccirillo CA, Putnam AL, Ritter T, Roncarolo MG, Sakaguchi S, Sánchez-Ramón S, Sawitzki B, Sofronic-Milosavljevic L, Sykes M, Tang Q, Vives-Pi M, Waldmann H, Witkowski P, Wood KJ, Gregori S, Hilkens CMU, Lombardi G, Lord P, Martinez-Caceres EM, Trzonkowski P. Front Immunol. 2017; 8:1844.
- Mitigating Ischemic Injury of Stem Cell-Derived Insulin-Producing Cells after Transplant. Faleo G, Russ HA, Wisel S, Parent AV, Nguyen V, Nair GG, Freise JE, Villanueva KE, Szot GL, Hebrok M, Tang Q. Stem Cell Reports. 2017 09 12; 9(3):807-819.
- Nanoporous Immunoprotective Device for Stem-Cell-Derived β-Cell Replacement Therapy. Chang R, Faleo G, Russ HA, Parent AV, Elledge SK, Bernards DA, Allen JL, Villanueva K, Hebrok M, Tang Q, Desai TA. ACS Nano. 2017 08 22; 11(8):7747-7757.
- Transplant trials with Tregs: perils and promises. Tang Q, Vincenti F. J Clin Invest. 2017 Jun 30; 127(7):2505-2512.
- Cutting Edge: Origins, Recruitment, and Regulation of CD11c+ Cells in Inflamed Islets of Autoimmune Diabetes Mice. Klementowicz JE, Mahne AE, Spence A, Nguyen V, Satpathy AT, Murphy KM, Tang Q. J Immunol. 2017 07 01; 199(1):27-32.
- Glucose-Stimulated Insulin Response of Silicon Nanopore-Immunoprotected Islets under Convective Transport. Song S, Yeung R, Park J, Posselt AM, Desai TA, Tang Q, Roy S. ACS Biomater Sci Eng. 2017 Jun 12; 3(6):1051-1061.
- Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes. Michels AW, Landry LG, McDaniel KA, Yu L, Campbell-Thompson M, Kwok WW, Jones KL, Gottlieb PA, Kappler JW, Tang Q, Roep BO, Atkinson MA, Mathews CE, Nakayama M. Diabetes. 2017 03; 66(3):722-734.
- Impact of Immune-Modulatory Drugs on Regulatory T Cell. Furukawa A, Wisel SA, Tang Q. Transplantation. 2016 Nov; 100(11):2288-2300.
- Restoring Regulatory T Cells in Type 1 Diabetes. Spence A, Tang Q. Curr Diab Rep. 2016 11; 16(11):110.
- Donor-Reactive Regulatory T Cell Frequency Increases During Acute Cellular Rejection of Lung Allografts. Greenland JR, Wong CM, Ahuja R, Wang AS, Uchida C, Golden JA, Hays SR, Leard LE, Rajalingam R, Singer JP, Kukreja J, Wolters PJ, Caughey GH, Tang Q. Transplantation. 2016 10; 100(10):2090-8.
- Virtual Global Transplant Laboratory Standard Operating Procedures for Blood Collection, PBMC Isolation, and Storage. Higdon LE, Lee K, Tang Q, Maltzman JS. Transplant Direct. 2016 Sep; 2(9):e101.
- Assessment of Immune Isolation of Allogeneic Mouse Pancreatic Progenitor Cells by a Macroencapsulation Device. Faleo G, Lee K, Nguyen V, Tang Q. Transplantation. 2016 06; 100(6):1211-8.
- Heightened Immune Activation in Fetuses with Gastroschisis May Be Blocked by Targeting IL-5. Frascoli M, Jeanty C, Fleck S, Moradi PW, Keating S, Mattis AN, Tang Q, MacKenzie TC. J Immunol. 2016 06 15; 196(12):4957-66.
- Silicon nanopore membrane (SNM) for islet encapsulation and immunoisolation under convective transport. Song S, Faleo G, Yeung R, Kant R, Posselt AM, Desai TA, Tang Q, Roy S. Sci Rep. 2016 Mar 24; 6:23679.
- Approaching a cure for type 1 diabetes. Tang Q, Desai TA. Nat Med. 2016 Mar; 22(3):236-7.
- Manipulating IL-2 and IL-2R in autoimmune diseases and transplantation. Zhang M, Tang Q. Immunotherapy. 2015; 7(12):1231-4.
- Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. Sci Transl Med. 2015 Nov 25; 7(315):315ra189.
- Targeting Treg signaling for the treatment of autoimmune diseases. Spence A, Klementowicz JE, Bluestone JA, Tang Q. Curr Opin Immunol. 2015 Dec; 37:11-20.
- Therapeutic window of interleukin-2 for autoimmune diseases. Tang Q. Diabetes. 2015 Jun; 64(6):1912-3.
- Polycaprolactone Thin-Film Micro- and Nanoporous Cell-Encapsulation Devices. Nyitray CE, Chang R, Faleo G, Lance KD, Bernards DA, Tang Q, Desai TA. ACS Nano. 2015 Jun 23; 9(6):5675-82.
- Immunotherapy: making the case for precision medicine. Bluestone JA, Tang Q. Sci Transl Med. 2015 Mar 25; 7(280):280ed3.
- Increased maternal T cell microchimerism in the allogeneic fetus during LPS-induced preterm labor in mice. Wegorzewska M, Le T, Tang Q, MacKenzie TC. Chimerism. 2014; 5(3-4):68-74.
- Therapeutic regulatory T cells subvert effector T cell function in inflamed islets to halt autoimmune diabetes. Mahne AE, Klementowicz JE, Chou A, Nguyen V, Tang Q. J Immunol. 2015 Apr 01; 194(7):3147-55.
- Antigen recognition in the islets changes with progression of autoimmune islet infiltration. Lindsay RS, Corbin K, Mahne A, Levitt BE, Gebert MJ, Wigton EJ, Bradley BJ, Haskins K, Jacobelli J, Tang Q, Krummel MF, Friedman RS. J Immunol. 2015 Jan 15; 194(2):522-30.
- Interpretation of transplant biopsies and immune responses following Treg cell therapy. Tang Q, Kang SM. Curr Opin Organ Transplant. 2014 Dec; 19(6):616-20.
- Fetal intervention increases maternal T cell awareness of the foreign conceptus and can lead to immune-mediated fetal demise. Wegorzewska M, Nijagal A, Wong CM, Le T, Lescano N, Tang Q, MacKenzie TC. J Immunol. 2014 Feb 15; 192(4):1938-45.
- Regulatory T-cell therapy in transplantation: moving to the clinic. Tang Q, Bluestone JA. Cold Spring Harb Perspect Med. 2013 Nov 01; 3(11).
- Direct and indirect antigen presentation lead to deletion of donor-specific T cells after in utero hematopoietic cell transplantation in mice. Nijagal A, Derderian C, Le T, Jarvis E, Nguyen L, Tang Q, Mackenzie TC. Blood. 2013 May 30; 121(22):4595-602.
- Altered balance between effector T cells and FOXP3+ HELIOS+ regulatory T cells after thymoglobulin induction in kidney transplant recipients. Tang Q, Leung J, Melli K, Lay K, Chuu EL, Liu W, Bluestone JA, Kang SM, Peddi VR, Vincenti F. Transpl Int. 2012 Dec; 25(12):1257-67.
- IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Lerner AG, Upton JP, Praveen PV, Ghosh R, Nakagawa Y, Igbaria A, Shen S, Nguyen V, Backes BJ, Heiman M, Heintz N, Greengard P, Hui S, Tang Q, Trusina A, Oakes SA, Papa FR. Cell Metab. 2012 Aug 08; 16(2):250-64.
- Regulatory T-cell therapy for transplantation: how many cells do we need? Tang Q, Lee K. Curr Opin Organ Transplant. 2012 Aug; 17(4):349-54.
- CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. Tang Q, Bluestone JA, Kang SM. J Mol Cell Biol. 2012 Feb; 4(1):11-21.
- B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice. Scapini P, Lamagna C, Hu Y, Lee K, Tang Q, DeFranco AL, Lowell CA. Proc Natl Acad Sci U S A. 2011 Oct 11; 108(41):E823-32.
- Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. Penaranda C, Tang Q, Bluestone JA. J Immunol. 2011 Aug 15; 187(4):2015-22.
- Requirements for prolongation of allograft survival with regulatory T cell infusion in lymphosufficient hosts. Brennan TV, Tang Q, Liu FC, Hoang V, Bi M, Bluestone JA, Kang SM. J Surg Res. 2011 Jul; 169(1):e69-75.
- The maternal immune response inhibits the success of in utero hematopoietic cell transplantation. Nijagal A, Wegorzewska M, Le T, Tang Q, Mackenzie TC. Chimerism. 2011 Apr; 2(2):55-7.
- Maternal T cells limit engraftment after in utero hematopoietic cell transplantation in mice. Nijagal A, Wegorzewska M, Jarvis E, Le T, Tang Q, MacKenzie TC. J Clin Invest. 2011 Feb; 121(2):582-92.
- IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, Gregoire S, Cagnard N, Carpentier W, Tang Q, Bluestone J, Chatenoud L, Klatzmann D, Salomon BL, Piaggio E. J Exp Med. 2010 Aug 30; 207(9):1871-8.
- Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Penaranda C, Tang Q, Ruddle NH, Bluestone JA. Diabetes. 2010 Jun; 59(6):1461-8.
- Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, Azuma M, Krummel MF, Bluestone JA. Nat Immunol. 2009 Nov; 10(11):1185-92.
- Amplification of autoimmune response through induction of dendritic cell maturation in inflamed tissues. Melli K, Friedman RS, Martin AE, Finger EB, Miao G, Szot GL, Krummel MF, Tang Q. J Immunol. 2009 Mar 01; 182(5):2590-600.
- T regulatory cells in autoimmune diabetes: past challenges, future prospects. Bluestone JA, Tang Q, Sedwick CE. J Clin Immunol. 2008 Nov; 28(6):677-84.
- Spontaneous development of a pancreatic exocrine disease in CD28-deficient NOD mice. Meagher C, Tang Q, Fife BT, Bour-Jordan H, Wu J, Pardoux C, Bi M, Melli K, Bluestone JA. J Immunol. 2008 Jun 15; 180(12):7793-803.
- Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Tang Q, Adams JY, Penaranda C, Melli K, Piaggio E, Sgouroudis E, Piccirillo CA, Salomon BL, Bluestone JA. Immunity. 2008 May; 28(5):687-97.
- The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Tang Q, Bluestone JA. Nat Immunol. 2008 Mar; 9(3):239-44.
- Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Travis MA, Reizis B, Melton AC, Masteller E, Tang Q, Proctor JM, Wang Y, Bernstein X, Huang X, Reichardt LF, Bluestone JA, Sheppard D. Nature. 2007 Sep 20; 449(7160):361-5.
- Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC. Endocrinology. 2007 Nov; 148(11):5136-44.
- Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone JA, Sayegh MH. Clin Immunol. 2007 Oct; 125(1):16-25.
- Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA. J Exp Med. 2006 Nov 27; 203(12):2737-47.
- Regulatory T-cell physiology and application to treat autoimmunity. Tang Q, Bluestone JA. Immunol Rev. 2006 Aug; 212:217-37.
- Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells. Scalapino KJ, Tang Q, Bluestone JA, Bonyhadi ML, Daikh DI. J Immunol. 2006 Aug 01; 177(3):1451-9.
- Imaging the function of regulatory T cells in vivo. Tang Q, Krummel MF. Curr Opin Immunol. 2006 Aug; 18(4):496-502.
- Plasmacytoid DCs and T(reg) cells: casual acquaintance or monogamous relationship? Tang Q, Bluestone JA. Nat Immunol. 2006 Jun; 7(6):551-3.
- Antigen-specific regulatory T cells--ex vivo expansion and therapeutic potential. Masteller EL, Tang Q, Bluestone JA. Semin Immunol. 2006 Apr; 18(2):103-10.
- Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. Trenado A, Sudres M, Tang Q, Maury S, Charlotte F, Grégoire S, Bonyhadi M, Klatzmann D, Salomon BL, Cohen JL. J Immunol. 2006 Jan 15; 176(2):1266-73.
- Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Tang Q, Adams JY, Tooley AJ, Bi M, Fife BT, Serra P, Santamaria P, Locksley RM, Krummel MF, Bluestone JA. Nat Immunol. 2006 Jan; 7(1):83-92.
- How do CD4+CD25+ regulatory T cells control autoimmunity? Bluestone JA, Tang Q. Curr Opin Immunol. 2005 Dec; 17(6):638-42.
- Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. Masteller EL, Warner MR, Tang Q, Tarbell KV, McDevitt H, Bluestone JA. J Immunol. 2005 Sep 01; 175(5):3053-9.
- Distinct roles of CTLA-4 and TGF-beta in CD4+CD25+ regulatory T cell function. Tang Q, Boden EK, Henriksen KJ, Bour-Jordan H, Bi M, Bluestone JA. Eur J Immunol. 2004 Nov; 34(11):2996-3005.
- Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Bluestone JA, Tang Q. Proc Natl Acad Sci U S A. 2004 Oct 05; 101 Suppl 2:14622-6.
- In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyhadi M, Bluestone JA. J Exp Med. 2004 Jun 07; 199(11):1455-65.
- Notch 1 signaling regulates peripheral T cell activation. Eagar TN, Tang Q, Wolfe M, He Y, Pear WS, Bluestone JA. Immunity. 2004 Apr; 20(4):407-15.
- Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. Tang Q, Henriksen KJ, Boden EK, Tooley AJ, Ye J, Subudhi SK, Zheng XX, Strom TB, Bluestone JA. J Immunol. 2003 Oct 01; 171(7):3348-52.
- CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo. Tang Q, Smith JA, Szot GL, Zhou P, Alegre ML, Henriksen KJ, Thompson CB, Bluestone JA. J Immunol. 2003 Feb 01; 170(3):1510-6.
- CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA. Nat Immunol. 2003 Feb; 4(2):182-8.
- The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Boden E, Tang Q, Bour-Jordan H, Bluestone JA. Novartis Found Symp. 2003; 252:55-63; discussion 63-6, 106-14.
- The Src family kinase Fyn mediates signals induced by TCR antagonists. Tang Q, Subudhi SK, Henriksen KJ, Long CG, Vives F, Bluestone JA. J Immunol. 2002 May 01; 168(9):4480-7.
- ERM-dependent movement of CD43 defines a novel protein complex distal to the immunological synapse. Allenspach EJ, Cullinan P, Tong J, Tang Q, Tesciuba AG, Cannon JL, Takahashi SM, Morgan R, Burkhardt JK, Sperling AI. Immunity. 2001 Nov; 15(5):739-50.
- Antigen-specific blockade of T cells in vivo using dimeric MHC peptide. O'Herrin SM, Slansky JE, Tang Q, Markiewicz MA, Gajewski TF, Pardoll DM, Schneck JP, Bluestone JA. J Immunol. 2001 Sep 01; 167(5):2555-60.
- Development and applications of surface-linked single chain antibodies against T-cell antigens. Griffin MD, Holman PO, Tang Q, Ashourian N, Korthäuer U, Kranz DM, Bluestone JA. J Immunol Methods. 2001 Feb 01; 248(1-2):77-90.
- Partial TCR signals delivered by FcR-nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. Smith JA, Tang Q, Bluestone JA. J Immunol. 1998 May 15; 160(10):4841-9.
- T cell receptor-gamma/delta cells protect mice from herpes simplex virus type 1-induced lethal encephalitis. Sciammas R, Kodukula P, Tang Q, Hendricks RL, Bluestone JA. J Exp Med. 1997 Jun 02; 185(11):1969-75.
- Proinflammatory functions of IL-2 in herpes simplex virus corneal infection. Tang Q, Chen W, Hendricks RL. J Immunol. 1997 Feb 01; 158(3):1275-83.
- Interferon gamma regulates platelet endothelial cell adhesion molecule 1 expression and neutrophil infiltration into herpes simplex virus-infected mouse corneas. Tang Q, Hendricks RL. J Exp Med. 1996 Oct 01; 184(4):1435-47.
- Ex vivo model of leukocyte migration into herpes simplex virus-infected mouse corneas. Chen W, Tang Q, Hendricks RL. J Leukoc Biol. 1996 Aug; 60(2):167-73.
- Inflammatory infiltration of the trigeminal ganglion after herpes simplex virus type 1 corneal infection. Liu T, Tang Q, Hendricks RL. J Virol. 1996 Jan; 70(1):264-71.
- Involvement of LFA-1 and ICAM-1 in the herpetic disease resulting from HSV-1 corneal infection. Dennis RF, Siemasko KF, Tang Q, Hendricks RL, Finnegan A. Curr Eye Res. 1995 Jan; 14(1):55-62.
- Herpes simplex virus glycoproteins E and I facilitate cell-to-cell spread in vivo and across junctions of cultured cells. Dingwell KS, Brunetti CR, Hendricks RL, Tang Q, Tang M, Rainbow AJ, Johnson DC. J Virol. 1994 Feb; 68(2):834-45.
- IL-8 gene expression in cultures of human corneal epithelial cells and keratocytes. Cubitt CL, Tang Q, Monteiro CA, Lausch RN, Oakes JE. Invest Ophthalmol Vis Sci. 1993 Oct; 34(11):3199-206.